Medical devices, healthcare technology and the business of care
510(k) clearance · K260191

Safety lancet (XXXVII)

Tianjin Huahong Technology Co., Ltd. · Decision date Mar 31, 2026

FDA DECISIONK260191

What did the FDA decide?

FDA records K260191 as a 510(k) premarket notification, with a decision dated Mar 31, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Mar 31, 2026

FDA source record

Regulatory record facts

Identifier
K260191
Regulatory pathway
510(k) premarket notification
Product code
FMK
Decision code
SESE
Decision date
Mar 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature.

Product code
FMK
FDA device class
2

FDA decision timeline

  1. K260191 received

    Application receipt date recorded by FDA.

  2. K260191 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code FMK

Product / regulatory recordCompanyPathwayDecision dateSource
Tianjin Huahong Technology Co., Ltd.510(k) clearanceSep 13, 2026FDA
Promisemed Hangzhou Meditech Co., Ltd.510(k) clearanceMay 1, 2026FDA
Ningbo Medsun Medical Co., Ltd.510(k) clearanceFeb 20, 2026FDA
Tianjin Huahong Technology Co., Ltd.510(k) clearanceFeb 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tianjin Huahong Technology Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Tianjin

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records